Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia

Leukemia

Volumn 17, Issue 4, 2003, Pages 746-750

  Campas C ^a   Dalmau, M ^a   Montaner, B ^a   Barragan M ^a   Bellosillo, B ^b   Colomer, D ^b   Pons, G ^a   Perez Tomas R ^a   Gil, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Apoptosis; B CLL; Caspases; Chemotherapy

Indexed keywords

CASPASE; DOXORUBICIN; FLUDARABINE; PRODIGIOSIN; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; ENZYME ACTIVATION; HUMAN; IC 50; LEUKEMIA CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0242584920     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402860     Document Type: Article

References (28)

1. Gerber NN. Prodigiosin-like pigments. CRC Crit Rev Microbiol 1975; 3: 469-485.
2. Montaner B, Navarro S, Piqué M, Vilaseca M, Martinell M, Giralt E et al. Prodigiosin from supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines. Br J Pharmacol 2000; 131: 583-593.
3. Díaz-Ruiz C, Montaner B, Pérez-Tomás R. Prodigiosin induces cell death and morphological changes indicative of apoptosis in gastric cancer cell line HGT-1. Histol Histopathol 2001; 16: 415-421.
4. Montaner B, Pérez-Tomás R. Prodigiosin-induced apoptosis in human colon cancer cells. Life Sci 2001; 68: 2025-2036.
5. Kipps TJ. Chronic lymphocytic leukaemia. Curr Opin Hematol 1998; 5: 244-253.
6. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukaemia: a bird of a different feather. J Clin Oncol 1999; 17: 399-408.
7. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998; 25: 11-18.
8. Bentley DP, Pepper CJ. The apoptotic pathway: a target for therapy in chronic lymphocytic leukemia. Hematol Oncol 2000; 18: 87-98.
9. Bellosillo B, Colomer D, Pons G, Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 1998; 100: 142-146.
10. Consoli U, El-Tounsi I, Sandoval A, Snell V, Kleine HD, Brown W et al. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood 1998; 91: 1742-1748.
11. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 2836-2843.
12. Bellosillo B, Piqué M, Barragán M, Castaño E, Villamor N, Colomer D et al. Aspirin induces apoptosis and activation of caspases in B-cell chronic lymphocytic leukaemia cells. Blood 1998; 92: 1406-1414.
13. Pepper C, Thomas A, Hoy T, Bentley P. Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones. Br J Haematol 1999; 104: 581-588.
14. Piqué M, Barragán M, Dalmau M, Bellosillo B, Pons G, Gil J. Aspirin induces apoptosis through mitochondrial cytochrome c release. FEBS Lett 2000; 480: 193-196.
15. Bellosillo B, Dalmau M, Colomer D, Gil J. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukaemia cells. Blood 1997; 89: 3378-3384.
16. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
17. Kawauchi K, Shibutani K, Yagisawa H, Kamata H, Nakatsuji S, Anzai H et al. A possible immunosuppressant, cycloprodigiosin hydrochloride, obtained from Pseudoalteromonas denitrificans. Biochem Biophys Res Commun 1997; 237: 543-547.
18. - symporter, induces apoptosis and differentiation in HL-60 cells. Int J Cancer 2000; 88: 121-128.
19. - symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Hepatology 1999; 30: 894-902.
20. - symporter, induces apoptosis in human breast cancer cell lines. J Cancer Res Clin Oncol 2000; 126: 191-197.
21. Kamata K, Okamoto S, Oka S, Kamata H, Yagisawa H, Hirata H. Cycloprodigiosin hydrochloride suppresses tumor necrosis factor (TNF) α-induced transcriptional activation by NF-κB. FEBS Lett 2000; 507: 74-80.
22. Han SB, Kim HM, Kim YH, Lee CW, Jang E, Son KH et al. T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens. Int J Immunopharmacol 1998; 20: 1-13.
23. Han SB, Park SH, Jeon YJ, Kim YK, Kim HM, Yang KH. Prodigiosin blocks T cell activation by inhibiting interleukin-2Rα expression and delays progression of autoimmune diabetes and collagen-induced arthritis. J Pharmacol Exp Ther 2001; 299: 415-425.
24. Azuma T, Watanabe N, Yagisawa H, Hirata H, Iwamura M, Kobayashi Y. Induction of apoptosis of activated murine splenic T cells by cycloprodigiosin hydrochloride, a novel immunosuppressant. Immunopharmacology 2000; 46: 29-37.
25. Songia S, Mortellaro A, Taverna S, Fornasiero C, Scheiber EA, Erba E et al. Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes. J Immunol 1997; 158: 3987-3995.
26. Mortellaro A, Songia S, Gnocchi P, Ferrari M, Fornasiero C, D'Alessio R et al. New immunosuppressive drug PNU156804 blocks IL-2 dependent proliferation and NF-κB and AP-1 activation. J Immunol 1999; 162: 7102-7109.
27. Stepkowski SM, Erwin-Cohen RA, Behbod F, Wang M, Qu X, Tejpal N et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002; 99: 680-689.
28. Melvin MS, Tomlinson JT, Saluta GR, Kucera GL, Lindquist N, Manderville RA. Double-strand DNA cleavage by copper-prodigiosin. J Am Chem Soc 2000; 122: 6333-6334.